Signs of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Hydrocodone | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Magnesium sulfate | The therapeutic efficacy of Metharbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Metharbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Mirtazapine | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Orphenadrine | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Pramipexole | Metharbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Metharbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Metharbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Metharbital. |
| Sodium oxybate | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Thalidomide | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Metharbital. |
| Mefloquine | The therapeutic efficacy of Metharbital can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Metharbital can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Metharbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Metharbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Metharbital. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Metharbital. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type B. |
| Ethanol | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Metharbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Metharbital. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Metharbital is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Metharbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Metharbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Metharbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Metharbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Metharbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Metharbital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Metharbital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Metharbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Metharbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Metharbital is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Metharbital is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Metharbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Metharbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Metharbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Metharbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Metharbital is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Metharbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Metharbital is combined with Bezitramide. |
| Morphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Metharbital is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Metharbital is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Metharbital is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Metharbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Metharbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Metharbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Metharbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Metharbital is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Metharbital is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Metharbital is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Metharbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Metharbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Metharbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Metharbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Metharbital is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Metharbital is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Metharbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Metharbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Metharbital is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Metharbital is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Metharbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Metharbital is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Metharbital is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Metharbital is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Metharbital is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Metharbital is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Metharbital is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Metharbital is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Metharbital is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Metharbital is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Metharbital is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Metharbital is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Metharbital is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Metharbital is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Metharbital is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Metharbital is combined with Naloxegol. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Metharbital is combined with Mecamylamine. |